2Q EARNINGS: Aegerion beats consensus, raises Juxtapid guidance
This article was originally published in Scrip
Aegerion Pharmaceuticals beat Wall Street consensus for its first full quarter of Juxtapid (lomitapide) sales and raised its guidance for full-year 2013 revenue from the homozygous familial hypercholesterolemia (HoFH) drug.
You may also be interested in...
ReCode, whose platform allows for organ-specific delivery of RNA therapies, plans to start clinical trials in 2022 for its two lead programs in primary ciliary dyskinesia and cystic fibrosis.
Public Company Edition: Benefitting from hope that biopharma interventions will help the coronavirus pandemic, the industry is faring better than others in the stock market, including the ability to launch IPOs. Also, BridgeBio leads recent financings and PDL is on track to dissolve by year-end.
Biopharma companies struggle with which trials, if any, to pause or delay. Lilly said it wants to ease the burden on health care facilities, while Galapagos said its choice is related to patient safety.